ArticleScientific reports2022

Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial.

Shun-Ichiro Komatsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.